Cantor Fitzgerald raises target for Amgen stock from USD 400 to USD 440

Published on 10/20/2026 at 11:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 10.05 billion, up 9.50 percent year over year. Amgen stock trades at EUR 382.00 on October 20, 2026.

Pipeline and reporting calendar

Cantor Fitzgerald set a USD 440.00 target on October 8, 2026, up from USD 400.00.
Amgen's second-quarter 2026 revenue rose 9.50 percent year over year to USD 10.05 billion.
Amgen is scheduled to report third-quarter 2026 results on November 3, 2026.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) is trading at EUR 382.00 at Lang & Schwarz on October 20, 2026 at 11:28 a.m. CEST. According to Investing.com on October 8, 2026, Cantor Fitzgerald raised its target for Amgen from USD 400.00 to USD 440.00 while maintaining a Neutral rating.

Target rises as results approach

The target revision places commercial execution at the center of the investment case. Cantor Fitzgerald said sustained performance across Amgen's core portfolio would be important through the second half of 2026, while MariTide top-line data are expected in the first half of 2027.

Amgen's second-quarter 2026 revenue was USD 10.05 billion, up 9.50 percent from USD 9.19 billion in the second quarter of 2025. The company reported GAAP net income of USD 2.38 billion and diluted earnings per share of USD 4.37 for the second quarter of 2026. These figures come from the standardized financial statements for the reported period.

What does the pipeline add?

On September 22, 2026, Amgen announced positive topline Phase 3 results for dazodalibep in systemic Sjogren's disease. The OASIZ 301 study met its Week 48 primary endpoint, and improvement in disease activity was observed from Week 4. On October 8, 2026, Cantor Fitzgerald set the USD 440.00 target after the earlier USD 400.00 target. On October 20, 2026, Amgen stock stood at EUR 382.00 at Lang & Schwarz.

Three dates shape the outlook

Amgen's recent sequence began with the September 22, 2026 dazodalibep announcement, followed by the October 8, 2026 Cantor Fitzgerald target increase and the October 20, 2026 Lang & Schwarz quote. The next stated date is November 3, 2026, when Amgen is scheduled to report third-quarter 2026 results after the market close, according to MarketBeat.

Pipeline progress meets execution risk

Reuters reported on September 22, 2026 that the dazodalibep trial met its main goal and that William Blair analyst Matt Phipps viewed the result as encouraging. The report also noted that OASIZ 303 is expected to produce results in the fourth quarter of 2026, making the follow-up study a key test for the program.

Amgen's stock was trading at EUR 382.00 at Lang & Schwarz on October 20, 2026 at 11:28 a.m. CEST. The primary listing is Nasdaq, where the company trades under AMGN in USD.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.